Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2026-03-03 00:00:00 ET · period of report 2026-03-01 · accession 0001613084-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-03 | 2026-03-01 | TRDA | Doshi Dipal | CEO, Dir | A - Grant | $0.00 | +139.4K | 555.1K | +34% | $0 |
| DM | 2026-03-03 | 2026-03-02+ | TRDA | Doshi Dipal | CEO, Dir | F - Tax | $11.73 | -29.1K | 526.0K | -5% | -$340.6K |
| D | 2026-03-03 | 2026-03-01 | TRDA | Doshi Dipal | CEO, Dir | A - Grant | $0.00 | +208.0K | 208.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-01 | A | A | 139,400 | $0.00 | 555,064 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. |
| 2 | Common | Common Stock | 2026-03-02 | F | D | 9,869 | $11.66 | 545,195 | D | — | — | (F2) Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-03-03 | F | D | 19,181 | $11.76 | 526,014 | D | — | — | (F2) Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-03-01 | A | A | 208,000 | $0.00 | 208,000 | D | $11.93 · — to 2036-03-01 | 208,000 Common Stock | (F5) 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030. |